Compositions containing human urine concentrate and methods for their manufacture, cell populations, human urine collection systems, muscle differentiation promoters and muscle injury treatment agents

By developing a composition containing human urine concentrate and serine proteoglycan nucleic acid, we have solved the technical challenges of muscle differentiation and muscle injury treatment, achieved efficient construction of human urine-derived cells and promotion of muscle differentiation, simplified the collection process and improved the effect of muscle injury repair.

CN123125320APending Publication Date: 2026-11-17NAT CENT OF NEUROLOGY & PSYCHIATRY
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202580022091.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-03-25
Filing Date
2025-03-21
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

In the existing technology, the role of serine proteoglycan in muscle tissue formation or muscle differentiation is unknown, and the construction method of human urine-derived cells is not yet mature, making it difficult to effectively promote muscle differentiation and treat muscle damage.

Method used

Compositions containing human urine concentrates, their manufacturing methods, cell populations, and human urine collection systems were developed. Sericin or nucleic acids that promote the expression of their core proteins were used as muscle differentiation promoters and muscle injury treatment agents to promote muscle differentiation and injury repair through administration or contact.

Benefits of technology

It improved the success rate of constructing human urine-derived cells, simplified the collection and preservation process, and enhanced the effects of promoting muscle differentiation and treating muscle damage.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

This invention discloses a composition containing human urine concentrate and its manufacturing method, cell population, human urine collection system, muscle differentiation promoter and muscle injury treatment agent, wherein the muscle differentiation promoter and muscle injury treatment agent contain serigin glucan or nucleic acid that promotes the expression of serigin glucan core protein.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This disclosure relates to compositions containing human urine concentrate and methods for manufacturing the same, cell populations, human urine collection systems, muscle differentiation promoters, and muscle injury treatment agents. Background Technology

[0002] Myotubes (also known as myotube cells) are immature muscle cells. Myotubes participate in the formation and regeneration of muscle fibers. For example, in cases of trauma, muscle tissue regeneration occurs at the site of muscle fiber injury through the generation and growth of myotubes.

[0003] Because collecting muscle fibers from human subjects is highly invasive, attempts have been made to directly induce myotubes from human urine-derived cells, which can be obtained non-invasively, as an alternative to muscle fibers used in drug evaluation, research, or biopsy of myopathy. For example, Patent Document 1 discloses a method for producing myotubes (myotube cells) from urine-derived cells, comprising: introducing MyoD1 (myoblast determination protein 1), one of the muscle regulatory factors (MRFs), into human urine-derived cells (urine cells); and exposing the urine-derived cells to at least one epigenetic regulatory compound. Furthermore, further technological development is being attempted regarding the construction of human urine-derived cells.

[0004] Serglycin is a type of proteoglycan (glycoprotein). It is present in and secreted from various cells in animals. As a major physiological function, serglycin is known to participate in immune function. For example, it is known to participate in the maintenance of homeostasis and regulation of storage function of secretory granules of immune cells, immune regulation, and apoptosis (Non-Patent Literature 1). Existing technical documents Patent documents

[0005] Patent Document 1: International Publication No. 2020 / 136696 Non-patent literature

[0006] Non-patent literature 1: Svein O. Kolset and Gunnar Pejler “Serglycin: A Structuraland Functional Chameleon with Wide Impact on Immune Cells”, The Journal of Immunol (2011) 187(10): 4927-4933. Non-patent literature 2: Kunitake K, Motohashi N, Inoue T, Suzuki Y, Aoki Y. "Characterization of CD90 / Thy-1 as a crucial molecular signature for myogenic differentiation in human urine-derived cells through single-cell RNAsequencing. Sci Rep. 2024; 14 (1): 2329. Summary of the Invention The problem that the invention aims to solve

[0007] The role of seriganin in muscle tissue formation or muscle differentiation is unknown.

[0008] The purpose of this disclosure is to provide muscle differentiation promoters and muscle injury treatment agents.

[0009] Furthermore, since human urine-derived cells are useful cells capable of differentiating and being induced into various cell types, not limited to myotubes, a method for constructing human urine-derived cells is needed. Therefore, another object of this disclosure is to provide an invention that facilitates the construction of such human urine-derived cells. Methods for solving problems

[0010] The inventors have discovered that serine proteoglycan has the ability to promote muscle differentiation and repair muscle damage.

[0011] In addition, the inventors have successfully developed compositions containing human urine concentrate that can help construct human urine-derived cells, methods for manufacturing the same, cell populations, and human urine collection systems.

[0012] For example, this disclosure relates to the following. [1-A] A muscle differentiation promoter containing serigin or a nucleic acid that promotes the expression of the serigin core protein. [1-B] A composition for promoting muscle differentiation, comprising serine or nucleic acid that promotes the expression of serine core protein. [1-C] A method for promoting muscle differentiation, comprising the step of administering serine or a nucleic acid that promotes the expression of a serine core protein to a subject in need of it. [1-D] Sericin used in promoting myoglobin differentiation or nucleic acid that promotes the expression of the core protein of sericin. [1-E] Use of serigan or nucleic acids that promote the expression of serigan core proteins in the manufacture of myodifferentiation promoters. [1-F] Use of serine or nucleic acid that promotes the expression of serine core protein in the manufacture of a composition for promoting muscle differentiation. [1-G] Use of serine or nucleic acids that promote the expression of serine core proteins in promoting myoblastic differentiation. [2-A] The muscle differentiation promoter according to [1-A] is a muscle differentiation promoter of human urine-derived cells or muscle satellite cells. [2-B] The composition according to [1-B] is used to promote muscle differentiation of human urine-derived cells or muscle satellite cells. [2-C] According to the use described in [1-E], wherein the muscle differentiation promoter is a muscle differentiation promoter of human urine-derived cells or muscle satellite cells. [2-D] According to the use described in [1-F], wherein the composition is for promoting muscle differentiation of human urine-derived cells or muscle satellite cells. [2-E] According to the use described in [1-G], it is used in promoting myoglobin differentiation of human urine-derived cells or muscle satellite cells. [3] A method for manufacturing a myotube, comprising the step of contacting a cell with serigin or a nucleic acid that promotes the expression of a serigin core protein. [4] According to the manufacturing method described in [3], wherein the cells are human urine-derived cells. [5] The manufacturing method according to [3] or [4] further includes the step of introducing the MYOD1 gene into the cell. [6-A] A muscle injury treatment agent containing serigin or a nucleic acid that promotes the expression of the serigin core protein. [6-B] A composition for treating muscle injury, comprising serigin glucan or nucleic acid that promotes the expression of the serigin glucan core protein. [6-C] A method for treating muscle injury comprising the step of administering serigin glucan or a nucleic acid that promotes the expression of a serigin glucan core protein to a subject in need of it. [6-D] Sericin used in the treatment of muscle injury or nucleic acid that promotes the expression of the core protein of sericin. [6-E] Use of serigan or nucleic acids that promote the expression of serigan core proteins in the manufacture of muscle injury treatment agents. [6-F] Use of serigan or nucleic acid that promotes the expression of serigan core protein in the manufacture of compositions for the treatment of muscle injury. [7] A human urine collection system comprising: a container having a receiving part for receiving human urine and a sealing mechanism capable of sealing the receiving part; and Antibiotics stored in the storage compartment. [8] A method for manufacturing human urine-derived cells, comprising the step of collecting human urine into the human urine collection system described in [7]. [9] A composition comprising human urine concentrate, dimethyl sulfoxide and serum.

[10] The composition according to [9], wherein the content of the dimethyl sulfoxide is 2.0 to 50% by volume relative to the total amount of the composition, and the content of the serum is 15 to 80% by volume relative to the total amount of the composition.

[11] The composition according to [9] or

[10] is used for the preparation of human urine-derived cells.

[12] A method for manufacturing human urine-derived cells, comprising: The process of concentrating human urine to obtain human urine concentrate. The process for preparing a mixture containing the human urine concentrate, dimethyl sulfoxide, and serum, and The process of freezing and preserving the mixture.

[13] A cell population with a diameter of less than 10 μm derived from human urine.

[14] A method for manufacturing human urine-derived cells, comprising the step of separating cells with a diameter of less than 10 μm from a cell population derived from human urine.

[15] The manufacturing method according to [8],

[12] or

[14] , wherein the human urine is human urine within 3 hours after urination. The method for manufacturing a myotube according to any one of

[16] [3] to [5], wherein the cell is a human urine-derived cell manufactured by any one of [7] to

[15] methods for manufacturing human urine-derived cells. Invention Effects

[0013] According to this disclosure, muscle differentiation promoters and muscle injury treatment agents can be provided.

[0014] Furthermore, according to this disclosure, compositions containing human urine concentrates, methods for manufacturing the same, cell populations, and human urine collection systems are also provided that can facilitate the construction of human urine-derived cells. Such compositions containing human urine concentrates, methods for manufacturing the same, cell populations, and human urine collection systems can, for example, help improve the success rate of constructing human urine-derived cells, simplify the collection and / or preservation of human urine used in the construction of human urine-derived cells, and / or improve the purity of the constructed human urine-derived cells. Attached Figure Description

[0015] Figure 1 A diagram of the lentiviral vector pLV[Exp]-Bsd-CMV>hSRGN[NM_001321053.2] used for SRGN gene introduction. Figure 2 This is a vector diagram of the lentiviral vector pLV[shRNA]-Bsd-U6>hSRGN used for shRNA delivery with SRGN-KD effect. Figure 3 This is a diagram showing the fluorescence image obtained by immunofluorescence staining in Experiment Example 4. Figure 4 To represent the experimental example 4 Figure 3 The graph shows the fusion index, with the results of CD90(-)MYOD1-UDCs represented in (A) and the results of CD90(+)MYOD1-UDCs represented in (B). Figure 5 This is a diagram showing the fluorescence image obtained by immunofluorescence staining in Experiment Example 5. Figure 6 To represent the experimental example 5 Figure 5 The graph shows the fusion index. Figure 7 This is a diagram showing the fluorescence image obtained by immunofluorescence staining in Experiment Example 6. Figure 8 To represent the experimental example 6 Figure 7 A graph showing the proportion of cells stained with DAPI and also with Edu in the proliferative evaluation, i.e., the proportion of proliferating cells. Figure 9 To represent the experimental example 6 Figure 7 A graph showing the fusion index in evaluating the differentiation capacity of myotubes. Figure 10 This is a diagram showing the fluorescence image obtained by immunofluorescence staining in Experiment Example 7. Figure 11 To indicate the basis and in Experiment Example 7 Figure 10 Similarly, the fluorescence images obtained were plotted as a graph showing the time-varying proportion of eMyHC-positive muscle fibers (eMyHC+ fibers (%)) as a marker of regenerating muscle fibers. Figure 12 This is a graph representing the results of muscle torque measurement in Experiment Example 7, standardized using the value of muscle torque measured on day 0. Detailed Implementation

[0016] The following describes the methods used to implement this disclosure, but this disclosure is not limited to the following implementation methods.

[0017] In this disclosure, when a protein or nucleic acid contains an amino acid sequence or base sequence that has more than 90% sequence identity with a specified amino acid sequence or base sequence, the protein or nucleic acid may have more than 91%, more than 92%, more than 93%, more than 94%, more than 95%, more than 96%, more than 97%, more than 98%, more than 99%, or more than 100% sequence identity with the specified sequence. In a preferred embodiment, it may have more than 95% sequence identity, and in the most preferred embodiment, it may have 100% sequence identity.

[0018] In this disclosure, when a protein or nucleic acid contains a sequence that is not 100% identical to a specified amino acid sequence or base sequence (i.e., the sequence identity is not 100%), the mutation can be a mutation selected from substitution, deletion, insertion, and addition among 1 to 10 residues or 1 to 30 bases, either continuously or dispersedly. In a preferred embodiment, the mutation can be a mutation selected from substitution, deletion, insertion, and addition among 1 to 3 residues or 1 to 10 bases, either continuously or dispersedly. In a more preferred embodiment, the mutation can be a mutation selected from substitution, deletion, insertion, and addition among 1 residue or 1 to 3 bases.

[0019] <Myotrophy Promoter> The first aspect of this disclosure relates to a muscle differentiation promoter (also known as a muscle differentiation promoting composition) containing serine or a nucleic acid that promotes the expression of a serine core protein.

[0020] Serigan is a glycan-modified form of the serigan core protein. In vivo, the serigan core protein, biosynthesized within cells, becomes glycan-modified serigan, a portion of which is secreted extracellularly. For example, the amino acid sequence of the physiologically present serigan core protein in humans is represented by sequence number 1, with the NCBI reference sequence number XP_054222221.1. Furthermore, in humans, the amino acid sequence of sequence number 1 is encoded by the mRNA shown in sequence number 2. The mRNA shown in sequence number 2 corresponds to bases 803 to 1279 of the mRNA with NCBI reference sequence number XM_054366246.1 (bases 1277 to 1279 are stop codons). Additionally, the amino acid sequence of the physiologically present serigan core protein in mice is represented by sequence number 3, with the NCBI reference sequence number NP_001345894.1. Additionally, in mice, the amino acid sequence of sequence number 3 is encoded by the mRNA shown in sequence number 4. The mRNA shown in sequence number 4 corresponds to bases 230 to 688 of the mRNA with NCBI reference sequence number NM_001358965.1 (bases 686 to 688 are stop codons).

[0021] In one embodiment, the serine proteoglycan may be a recombinant serine proteoglycan. The serine proteoglycan is preferably derived from the animal from which the myodifferentiation promoter is administered or from the animal whose cells have come into contact with the serine proteoglycan. For example, when the myodifferentiation promoter is administered to a human, or when the cells in contact with the serine proteoglycan are human-derived cells, the serine proteoglycan is preferably a human-derived recombinant. The recombinant serine proteoglycan may be a serine proteoglycan obtained by expressing the proteoglycan in cells of an animal source and then isolating and purifying it according to methods commonly practiced by those skilled in the art. For example, the recombinant serine proteoglycan may be a serine proteoglycan obtained by introducing a nucleic acid containing a base sequence encoding the core protein of serine proteoglycan (e.g., a nucleic acid containing a base sequence encoding human serine proteoglycan, such as the sequence described in Serial No. 2) into human-derived cells, causing the human-derived cells to express serine proteoglycan, and then isolating and purifying it from the cells and / or its culture supernatant. Such recombinant serigin can use commercially available serigin from suppliers such as abcam (e.g., recombinant human serigin (ab116977)), or it can use serigin that is substantially the same.

[0022] In one embodiment, the serigan core protein may be a protein comprising an amino acid sequence having a sequence identity of more than 90% with the amino acid sequence described in Serial No. 1 or 3, or a protein comprising an amino acid sequence having a sequence identity of more than 90% with the amino acid sequence described in Serial No. 1. In another embodiment, the serigan core protein may be a protein composed of an amino acid sequence having a sequence identity of more than 90% with the amino acid sequence described in Serial No. 1 or 3, or a protein composed of an amino acid sequence having a sequence identity of more than 90% with the amino acid sequence described in Serial No. 1.

[0023] The glycan modification of the serigin in the myodifferentiation promoter of the first aspect, specifically the modification of the core protein of the serigin, can be a physiologically possible glycan modification in vivo or in cells from which the myodifferentiation promoter is administered, such as O-glycosylation. In one embodiment, the glycan modification of the core protein of the serigin can be O-glycosylation comprising at least one glycan selected from chondroitin sulfate and heparan sulfate. In a preferred embodiment, the glycan modification of the core protein of the serigin can be a modification of the glycan consisting of a primary glycan of chondroitin sulfate or heparan sulfate that directly O-glycosylates the core protein of the serigin, and a secondary glycan that further modifies the primary glycan, or a modification by a mucopolysaccharide (glycosaminoglycan) composed of these. In these cases, in one embodiment, chondroitin sulfate may be at least one selected from chondroitin sulfate A, chondroitin sulfate C, chondroitin sulfate D, chondroitin sulfate E, chondroitin sulfate K, chondroitin sulfate 4 (Non-Patent Document 1), and chondroitin sulfate diB (Non-Patent Document 1). Additionally, in a preferred embodiment, chondroitin sulfate may be at least one selected from chondroitin sulfate E, chondroitin sulfate 4, and chondroitin sulfate diB, and may be chondroitin sulfate E, chondroitin sulfate 4, or chondroitin sulfate diB. In these cases, in a preferred embodiment, heparan sulfate may be heparin.

[0024] The nucleic acid that promotes the expression of the serine core protein can be any nucleic acid capable of promoting the expression of the serine core protein. In one embodiment, the nucleic acid containing the base sequence encoding the serine core protein can be a nucleic acid containing the base sequence encoding the serine core protein that promotes the expression of the serine core protein. In a preferred embodiment, the nucleic acid containing the base sequence encoding the serine core protein can be mRNA containing the base sequence encoding the serine core protein, or a nucleic acid that generates the mRNA after eukaryotic transcription and splicing. The base sequence encoding the serine core protein can be, for example, a base sequence with more than 90% sequence identity to, the ribonucleic acid base sequence described in sequence number 2 or 4 (equivalent to the mRNA sequence), a deoxyribonucleic acid base sequence complementary to the ribonucleic acid base sequence (equivalent to the cDNA sequence), or a ribonucleic acid base sequence that generates the ribonucleic acid base sequence after eukaryotic transcription and splicing (equivalent to the pre-mRNA sequence). In one embodiment, the nucleic acid containing the base sequence encoding the serine core protein can be an mRNA containing a base sequence having at least 90% sequence identity with the base sequence described in Serial No. 2 or 4, a nucleic acid (cDNA) complementary to the mRNA, a nucleic acid (pre-mRNA) generated by eukaryotic transcription and splicing, or a vector incorporating both. In a preferred embodiment, the nucleic acid containing the base sequence encoding the serine core protein can be an mRNA containing a base sequence having at least 90% sequence identity with the base sequence described in Serial No. 2, a nucleic acid (pre-mRNA) generated by eukaryotic transcription and splicing, or a viral vector (e.g., a lentiviral vector, adenovirus vector, or adeno-associated virus vector) incorporating both. In a most preferred embodiment, the nucleic acid containing the base sequence encoding the serine core protein can be an mRNA composed of a base sequence having at least 90% sequence identity with the base sequence described in Serial No. 2, or a viral vector incorporating the mRNA.

[0025] In one embodiment, the content of seriganin or nucleic acids that promote the expression of seriganin core proteins in the myoglobin differentiation promoter is not particularly limited, and may be, for example, 0.001 to 100% by mass based on the total amount of the formulation. In another embodiment, the myoglobin differentiation promoter may consist solely of seriganin or nucleic acids that promote the expression of seriganin core proteins. In yet another embodiment, the myoglobin differentiation promoter may include seriganin or nucleic acids that promote the expression of seriganin core proteins as an active ingredient.

[0026] In this disclosure, myodifferentiation refers to the differentiation of stem cell-like cells into myocytes or their precursor cells, or the differentiation of myosatellite cells into myocytes (e.g., myotubes or myoblasts).

[0027] According to the first aspect, myoglobin differentiation promoters can be used as drugs or reagents.

[0028] <Used as a muscle differentiation promoter in pharmaceuticals> When a myoglobin differentiation promoter is used as a drug, it can promote cell differentiation in the subject to which the myoglobin differentiation promoter is administered. This increases the proportion of muscle cells in the subject, enabling the treatment of diseases related to intrinsic or extrinsic deficiencies in muscle cells.

[0029] When myoglobin differentiation promoters are used as drugs, in addition to nucleic acids that promote the expression of serigan and serigan core protein, they may also contain additives commonly used in the field of formulation technology, such as excipients, buffers, stabilizers, antioxidants, binders, disintegrants, fillers, emulsifiers, and flow additives.

[0030] When myoglobin promoters are used as drugs, the serine or nucleic acid that promotes the expression of the serine core protein contained in the myoglobin promoter can be encapsulated in a drug carrier capable of delivering a cell membrane-permeable component into the cell. Examples of such drug carriers include liposomes and capsids.

[0031] When a muscle differentiation promoter is used as a drug, the recipient can be a human or a non-human animal. Non-human animals can be mammals other than humans, specifically mice, rats, guinea pigs, hamsters, chimpanzees, dogs, cats, pigs, or rabbits. In a preferred embodiment of using a muscle differentiation promoter as a drug, the recipient can be a human. That is, in a preferred embodiment of using a muscle differentiation promoter as a drug, the muscle differentiation promoter can be administered to a human subject.

[0032] When myoglobin differentiation promoters are used as drugs, they can be administered orally or non-orally. Non-oral administration can include intravenous injection, subcutaneous injection, intramuscular injection, spinal injection, transdermal administration, eye drops, nasal drops, etc. As a specific dosage example, when administering the formulation to an adult male (weighing 60 kg), the daily dosage is typically calculated based on the amount of active ingredient and ranges from 0.0001 μg to 10000 mg / day / person.

[0033] When the muscle differentiation promoter of the first aspect is used as a drug, muscle injury can be cited as one of the diseases targeted for treatment. Muscle injury refers to a state in which muscle fibers or tissues are damaged due to some external or internal cause, typically caused by physical impact or pressure from an accident. The inventors have discovered that differentiation into myocytes is promoted in muscle satellite cells in contact with serigan. Therefore, without being bound by any theory, it is considered that by administering the muscle differentiation promoter of the first aspect to a subject with muscle injury, the differentiation of muscle satellite cells at the site of muscle injury into myocytes can be promoted, thereby treating the muscle injury. The inventors have discovered that by administering the muscle differentiation promoter of the first aspect to an animal with muscle injury, repair of the muscle injury can be observed. Thus, one embodiment of the first aspect of this disclosure may relate to a muscle injury treatment agent (or composition for treating muscle injury) containing serigan or a nucleic acid that promotes the expression of the serigan core protein. In addition, this embodiment may also relate to a muscle injury treatment method comprising the step of administering serigan or a nucleic acid that promotes the expression of the serigan core protein to a subject in need of it. Additionally, this embodiment may also involve a serigan or a nucleic acid that promotes the expression of the serigan core protein for use in the treatment of muscle injury. In these cases, the composition, dosage form, target population, and dosage of the formulation may be the same as those described in the muscle differentiation promoters of the first aspect. A formulation is a muscle injury treatment agent (or has a muscle injury treatment effect) by, for example, by administering the formulation and observing pathological repair and / or functional repair of muscle injury (e.g., increased muscle strength) in the target population compared to the absence of administration.

[0034] <Myotrophic agents used as reagents> When the myoglobin differentiation promoter of the first aspect is used as a reagent, the myoglobin differentiation promoter can be utilized in in vitro methods for inducing myoglobin differentiation of cells.

[0035] When myoglobin differentiation promoters are used as reagents, in addition to nucleic acids that promote the expression of serine and serine core proteins, they may also contain additives commonly used in in vitro methods, such as buffers, antioxidants, surfactants, and pH adjusters.

[0036] When a myoglobin differentiation promoter is used as a reagent, the cells that come into contact with the promoter can be cells whose myoglobin differentiation has been promoted under the action of the promoter, or cells that are likely to be promoted, such as stem cells. That is, one type of myoglobin differentiation promoter can be a stem cell differentiation promoter.

[0037] In a preferred embodiment of using a muscle differentiation promoter as a reagent, the cells contacted by the muscle differentiation promoter may be human urine-derived cells. In other words, a preferred embodiment of the muscle differentiation promoter may be a muscle differentiation promoter derived from human urine-derived cells. Human urine-derived cells (UDCs) are primary cultured cells from the upper urinary tract that can be collected from human urine. It is known that the cell population of human urine-derived cells is a heterogeneous cell population containing cells of various morphologies and origins, such as renal epithelial cells and urinary tract epithelial cells. The human urine-derived cells disclosed herein may be, for example, cells isolated from urine collected from a human subject or its culture, or cells obtained by culturing cells isolated from urine collected from a human subject. The method of cell isolation is not particularly limited as long as it is a method that can isolate the cells from urine or its culture containing cells; for example, it may be centrifugation or filtration, preferably centrifugation. Since human urine-derived cells can be prepared from urine excreted by a human, they are non-invasively collectible, stem cell-like cells. Therefore, when the muscle differentiation promoter is a muscle differentiation promoter for human urine-derived cells, cells with human-derived stem cell characteristics can be obtained non-invasively.

[0038] Methods for preparing human urine-derived cells are well known in the art and are not particularly limited. For example, they can be prepared by the methods shown below. After centrifuging urine collected from human subjects and removing the supernatant, the pellets were mixed with the initial culture medium (a mixture of equal volumes of high-glucose DMEM (GE Healthcare, Logan, UT; SH30022.FS) and Ham's F-12 Nutrient Mix (Thermo Fisher Scientific; 11765-054), and supplemented with REGM Single Quots (Lonza, Basel, Switzerland; CC-4127), 10% tetracycline-free fetal bovine serum (Clontech; 631106), 1% penicillin / streptomycin, and 0.5 μg / mL amphotericin B) and incubated at approximately 37°C. Then, the pellets were incubated with proliferation medium (a mixture of equal volumes of REGM Bullet Kit (Lonza; CC-3190) and high-glucose DMEM, and supplemented with 15% tetracycline-free fetal bovine serum and 0.5% Glutamax (Thermo Fisher Scientific). Cells were cultured in a mixture containing 0.5% non-essential amino acids (Thermo Fisher Scientific; 11140-050), 2.5 ng / mL basic fibroblast growth factor (bFGF) (Sigma, St Louis, USA; F0291), PDGF-AB (Peprotech, Rocky Hill, NJ; 100-00AB), EGF (Peprotech; AF-100-15), 1% penicillin / streptomycin, and 0.5 μg / mL amphotericin B. Cells that formed colonies were selected from approximately several days to two weeks after the start of culture. These cells, after multiple passages, became stable cell lines with similar characteristics.

[0039] As an example of inducing myodifferentiation of cells in vitro, the manufacture of myotubes can be cited. Myotubes (also known as "myotube cells") are immature muscle cells. By manufacturing myotubes, myotubes can be obtained, for example, for use in high-throughput screening of therapeutics and preventative agents targeting myotubes. Additionally, by manufacturing myotubes, for example, cell populations of myotubes can be obtained from cells derived from various myopathy or muscular dystrophy patients (e.g., cells derived from human urine). These cell populations are useful, for example, for detections related to therapeutics and preventative agents useful to individual patients without actual drug administration (so-called companion diagnostics), or for disease studies by obtaining genetic profiles and phenotypes in myotubes from individual patients.

[0040] <Mechanisms for manufacturing myotubes, methods for inducing myodifferentiation, and methods for enhancing myodifferentiation capacity> By using the myoblast differentiation promoter of the first aspect as a reagent, myoblast differentiation of cells can be promoted to obtain myoblasts. Therefore, one embodiment of the first aspect may relate to a method of manufacturing a myoblast (hereinafter also referred to as a "myoblast manufacturing method"), which includes contacting cells with seriganin or a nucleic acid that promotes the expression of the seriganin core protein (contact step). In one embodiment, the cells used in the contact step are cells comprising human-derived stem cells. In a preferred embodiment, the cells used in the contact step are human urine-derived cells.

[0041] By using the myoglobin differentiation promoter of the first aspect as a reagent, cell myoglobin differentiation can be promoted. Therefore, one embodiment of the first aspect may relate to a myoglobin differentiation induction method (hereinafter also referred to as a "myoglobin differentiation induction method") comprising contacting cells with seriganin or nucleic acids that promote the expression of seriganin core proteins (contact step). In one embodiment, the cells used in the contact step are cells comprising human-derived stem cells. In a preferred embodiment, the cells used in the contact step are human urine-derived cells.

[0042] By using the myoglobin differentiation promoter of the first aspect as a reagent, cells become more readily capable of myoglobin differentiation. Therefore, one embodiment of the first aspect may relate to a method for enhancing the myoglobin differentiation capacity of cells (hereinafter also referred to as a "myoglobin differentiation capacity enhancement method"), comprising a step of contacting cells with seriganin or nucleic acids that promote the expression of seriganin core proteins (a contact step). In one embodiment, the cells used in the contact step are cells comprising human-derived stem cells. In a preferred embodiment, the cells used in the contact step are human urine-derived cells.

[0043] In the contacting process, cells are contacted with serigan or nucleic acids that promote the expression of the serigan core protein in a cell culture medium. The concentration of serigan in the contacting process is not particularly limited, and can be, for example, 0.3–300 ng / mL. The concentration of the nucleic acid that promotes the expression of the serigan core protein in the contacting process is not particularly limited, and can be, for example, 1 ng / mL–10 mg / mL or 3 μg / mL–300 μg / mL. The culture medium in the contacting process is not particularly limited, and any culture medium commonly used by those skilled in the art can be used. Examples of culture media include proliferation media, differentiation media (such as DMEM with GlutaMAX-I containing high glucose (Thermo Fisher Scientific; 10569-010), 5% horse serum, ITS Liquid Media Supplement (Sigma; I3146), 1 μg / mL doxycycline), etc.

[0044] The contact time (culture period) in the contact process is not particularly limited, and can range from 8 hours to 4 weeks. The contact method in the contact process is not particularly limited; for example, a nucleic acid or drug carrier encapsulating a substance that promotes the expression of seriganin, seriganin core protein, or a solution thereof can be added to the cell suspension. Alternatively, a solution of a nucleic acid or drug carrier encapsulating a substance that promotes the expression of seriganin, seriganin core protein, or a substance thereof can be added to adherent or granular cells. The contact conditions in the contact process are not particularly limited; for example, the culture temperature can be set to a temperature suitable for cell culture, such as 30–40°C, preferably about 37°C, and the pH can be maintained, for example, near neutral. The contact period in the contact process can be, for example, more than 2 days and less than 28 days; as an example, it can be 7 days. In one embodiment, when the nucleic acid promoting the expression of seriganin core protein is a viral vector, the cells can be contacted with the viral vector (not encapsulated by a drug carrier). In another embodiment, when the nucleic acid promoting the expression of seriganin core protein is mRNA, the cells can be contacted with mRNA encapsulated in liposomes. Such liposomes can be prepared using commercially available liposome transfection reagents such as the Lipofectamine (registered trademark) series (ThermoFisher Scientific), following methods commonly used by those skilled in the art. The contact process may involve selecting cells from which nucleic acids promoting the expression of the serine core protein have been introduced. Such selection can be performed according to methods commonly used by those skilled in the art, for example, by contacting cells introduced with nucleic acids promoting the expression of the serine core protein and a blast fungicide resistance gene with blast fungicide.

[0045] In one approach, the myotube manufacturing method, the myotube differentiation induction method, and the myotube differentiation capacity enhancement method may include a step of inducing cells after the contact step into myotubes (induction step). The method for inducing cells into myotubes in the induction step is not particularly limited as long as it is a method capable of inducing the cells into myotubes.

[0046] In one approach, myotube manufacturing methods, myodifferentiation induction methods, and myodifferentiation capacity enhancement methods may include a step of introducing the MYOD1 gene into cells (the introduction step) as an induction step, or as a substitute for the induction step. MYOD1 (myoblast determination protein 1) is a muscle-specific transcription factor listed as one of the muscle regulatory factors and belongs to the MYOD family. It is known that introducing the MYOD1 gene into fibroblasts, etc., can induce myotube differentiation. The introduction step can be performed before, simultaneously with, or after the contact step.

[0047] The MYOD1 gene is well known in the art and is not particularly limited, but the human MYOD1 gene is preferred. The sequence of the MYOD1 gene, such as the human MYOD1 gene sequence, is registered in GenBank (National Center for Biotechnology Information (NCBI)) with accession number NM_002478.4.

[0048] The introduction of the MYOD1 gene into human urine-derived cells can be performed using methods known in the art, such as those described in Patent Document 1. For example, the MYOD1 gene can be cloned and integrated into a suitable expression vector (e.g., a retroviral vector). In addition to the MYOD1 gene, the expression vector may also contain promoters, enhancers, and selection marker genes. The promoter can be appropriately selected, with inducible promoters being preferred. When cells begin myoblast differentiation due to MYOD1 expression, their proliferative capacity is significantly reduced. However, by using an inducible promoter, cell proliferation caused by inhibiting myoblast differentiation and the induction of myoblast differentiation can be controlled. Specifically, for example, after introducing the MYOD1 gene into cells using the TRE3GS promoter as an inducible promoter, the cells with the MYOD1 gene introduced are proliferated. Then, doxycycline (Dox) is added to the culture medium to activate the promoter, causing MYOD1 gene expression and inducing myoblast differentiation. Furthermore, selection marker genes are not mandatory, but since cells with the MYOD1 gene introduced can be easily selected, integration into the expression vector is preferred. Examples of selectable marker genes include puromycin resistance genes, neomycin resistance genes, bleomycin resistance genes, hygromycin resistance genes, and blast fungicide resistance genes. Such expression vectors are introduced into cells using methods known in the art, such as commercially available transfection reagents. The selection of the introduced cells is also known in the art; for example, in the case where a puromycin resistance gene is inserted into the expression vector, cells exhibiting resistance to puromycin are selected.

[0049] The conditions for introducing the MYOD1 gene in the introduction process are not particularly limited. For example, proliferation medium or differentiation medium can be used as the culture medium. Additionally, the culture temperature can be set to a temperature suitable for cell culture, such as 30–40°C, preferably about 37°C, and the pH should be maintained near neutral. The culture period can range from 1 hour to 4 weeks, preferably about 1 day to 2 weeks.

[0050] Thus, the muscle differentiation promoter in the first aspect can be a muscle differentiation promoter derived from human urine cells or muscle satellite cells. Muscle satellite cells are a type of adult stem cell that typically exists in a dormant state, but are isochronously activated, proliferate, and differentiate into muscle cells such as myotubes upon muscle injury. The muscle satellite cells can be human muscle satellite cells.

[0051] Thus, the first aspect of this disclosure can also relate to a method for promoting myocardial differentiation, comprising the step of administering serine or a nucleic acid that promotes the expression of a serine core protein to a subject in need. Additionally, the first aspect of this disclosure can also relate to serine or a nucleic acid that promotes the expression of a serine core protein for use in promoting myocardial differentiation.

[0052] <Methods for manufacturing cells derived from human urine> The second aspect of this disclosure relates to a method for manufacturing human urine-derived cells. Hereinafter, one embodiment of the method for manufacturing human urine-derived cells according to the second aspect of this disclosure (hereinafter also referred to as the "manufacturing method of the second aspect") will be described, but the manufacturing method of the second aspect is not limited to the following embodiment. For example, the manufacturing method of the second aspect can be implemented more specifically according to the method described in the embodiments.

[0053] The manufacturing method according to one embodiment of the second aspect (hereinafter also referred to as "the manufacturing method of one embodiment") includes: a step of collecting human urine (collection step); a step of concentrating human urine to obtain human urine concentrate (concentration step); a step of preparing a mixture containing human urine concentrate, dimethyl sulfoxide and serum (mixing step); a step of freezing the mixture (freezing step); a step of thawing the frozen mixture (thawing step); a step of separating cells with a diameter of less than 10 μm from a cell population derived from human urine (separation step); and a step of culturing cells derived from human urine (culturing step).

[0054] In the collection process, human urine is collected. For example, human urine can be collected by having a person urinate into a glass or plastic bottle that can recycle and preserve the liquid components. Alternatively, human urine can be collected by having a person urinate into a cup or similar container and then transferring the collected urine into a bottle. There is no particular limitation on the amount of human urine collected in the collection process; it can be the total amount or a portion of the urine excreted in a single urination, for example, 25 to 250 mL.

[0055] In one embodiment, the bottle (container) used in the collection process has a receiving section and a sealing mechanism. The receiving section receives the human urine collected in the collection process. The sealing mechanism is a mechanism capable of sealing the receiving section, such as a screw cap or flip cap, a clamp, or a heat seal; as an example, a screw cap.

[0056] In one embodiment, the collection process uses a bottle containing antibiotics. The antibiotics are stored in the collection section before human urine is collected. Therefore, since the antibiotics dissolve immediately upon entering the collection section, bacterial infection of the collected urine can be prevented. For example, the antibiotic is at least one selected from penicillin antibiotics, cephalosporin antibiotics, macrolide antibiotics, tetracycline antibiotics, and aminoglycoside antibiotics. Examples of antibiotics include penicillin and streptomycin. The amount of antibiotic is, for example, 0.1 μg or more and 1 kg or less per bottle (or per 25-250 mL of human urine), such as 20,000 μg. The amount of antibiotic is, for example, 1.0 × 10⁻⁶ units or more and 1.0 × 10⁻⁶ units per bottle (or per 25-250 mL of human urine). 8 Units, as an example, are 2.0 × 10 4 Units.

[0057] In one embodiment, the collection section of the bottle used in the collection process contains an antifungal drug in addition to antibiotics. The antibiotics and antifungal drug are stored in the collection section before human urine is collected. Therefore, since the antibiotics and antifungal drug dissolve immediately after the human urine is collected, bacterial and fungal infections of the collected urine can be prevented. For example, the antifungal drug is at least one selected from azole antifungals, polyene antifungals, allylamine antifungals, and echinocandins. Amphotericin B is an example of an antifungal drug. The amount of antifungal drug is, for example, 1 ng or more and 10 g or less per bottle (or per 25-250 mL of human urine), and as an example, 0.2 μg.

[0058] In one embodiment of the collection process, the time from the subject urinating to the collection portion of the bottle is, for example, within 3 hours, but could also be within 1 hour, 15 minutes, 5 minutes, 1 minute, or 15 seconds. A time of 15 seconds or less occurs when the subject urinates directly into the collection portion of the bottle. If the time from the subject urinating to the collection portion of the bottle is within the aforementioned upper limit, bacterial infection of the collected urine can be suppressed, and the success rate of constructing urine-derived cells can be improved.

[0059] In the concentration process, human urine is concentrated to obtain a concentrated human urine product. The concentrated human urine product obtained in the concentration process is a cell suspension with a higher concentration of cellular components than in human urine. The concentration method used in the concentration process is a method that does not significantly affect cell survival and proliferation, such as concentration by centrifugation at temperatures above 4°C and below 40°C or by removing the supernatant after settling. In one embodiment of the concentration process, firstly, human urine collected in the collection process is transferred into multiple conical tubes in increments of approximately 50 mL. These conical tubes are then centrifuged at 4–30°C and 100–1000 × g for 2–30 minutes, and the supernatant is recovered until 1–10 mL is obtained. The clumps of cellular components are resuspended in the remaining liquid, diluted with a buffer solution such as physiological saline as needed, and a total of 20–50 mL of the cell suspension is collected into one conical tube. The conical tube was centrifuged at 4–30°C and 100–1000 × g for 2–30 minutes, and the supernatant was then recovered until 1–10 mL was obtained. This yielded a concentrated human urine sample containing cellular components from the collected urine (e.g., 25–250 mL) and approximately 1–10 mL of liquid components.

[0060] In the mixing step, a mixture (composition) containing human urine concentrate, dimethyl sulfoxide, and serum is prepared. The resulting mixture (composition) can be used as a composition for the preparation of human urine-derived cells. In one embodiment of the mixing step, dimethyl sulfoxide and serum are added to the human urine concentrate obtained in the concentration step. The amount of dimethyl sulfoxide added relative to the total amount of the mixture can be 2.0–50 vol%, 2.5–30 vol%, 3.0–20 vol%, or 3.5–10 vol%, as an example, 5 vol%. The amount of serum added relative to the total amount of the mixture can be 15–80 vol%, 20–70 vol%, 25–60 vol%, or 30–50 vol%. The serum is, for example, fetal bovine serum (FBS). As an addition of dimethyl sulfoxide and serum, a solution containing them, namely CELLBANKER (registered trademark) 1 (Takara Bio, CB011), may be added, for example, at a volume of 0.01 to 100 times, 0.1 to 10 times, or 0.3 to 3 times that of human urine concentrate. As an example, it may be added at a volume of 1 times that of human urine concentrate.

[0061] In the cryopreservation process, the composition containing human urine concentrate, dimethyl sulfoxide, and serum is cryopreserved. The cryopreservation temperature can be any temperature at which the composition is frozen, for example, -100°C or higher and -20°C or lower, preferably -100°C or higher and -50°C or lower; as an example, -80°C. The cryopreservation period is not particularly limited, for example, more than one week, more than one month, more than three months, more than one year, or more than two years, or less than 100 years, less than 10 years, less than 5 years, less than 3 years, or less than 2 years. In one embodiment of the cryopreservation process, the mixture obtained in the mixing process is stored at -80°C for more than one year. From the viewpoint of improving the success rate of constructing human urine-derived cells, the freezing in one embodiment of the cryopreservation process is preferably performed within 8 hours after the start of the collection process (i.e., when the subject urinates), more preferably within 3 hours. In addition, from the viewpoint of improving the success rate of constructing human urine-derived cells, the freezing process in one embodiment is preferably carried out within 1 hour after the human urine concentrate and dimethyl sulfoxide are mixed in the mixing process, more preferably within 15 minutes, and even more preferably within 3 minutes.

[0062] In the thawing process, a frozen mixture (composition) containing human urine concentrate, dimethyl sulfoxide, and serum is thawed. In one embodiment, the frozen mixture obtained in the cryopreservation process is thawed. The thawing method in the thawing process is one that does not significantly affect cell survival and proliferation, such as static incubation at 25–45°C. The thawed product obtained in the thawing process can be used in the following aliquot or culture processes by diluting it with a culture medium or by separating the cells through centrifugation and then resuspending the cells in a culture medium.

[0063] In the separation process, cells with a diameter of 10 μm or less are separated from a cell population derived from human urine. In one embodiment, the separation process involves separating a cell population with a diameter of 10 μm or less from a cell population contained in the melt or its culture product obtained in the melting process. Human urine contains cells other than those derived from human urine (e.g., cells that are not stem cell-like). Here, the proportion of human urine-derived cells with a diameter of 10 μm or less is high. On the other hand, the proportion of cells other than human urine-derived cells (mixed cells) with a diameter exceeding 10 μm is high in human urine. Therefore, by separating cells with a diameter of 10 μm or less from a cell population derived from human urine, the proportion of human urine-derived cells can be increased.

[0064] Regarding the method for separating cells with a diameter of 10 μm or less in the separation process, there is no particular limitation as long as it is a method commonly used by those skilled in the art, such as using a flow cytometer or a cell sorter. In the separation process of one embodiment, as a flow cytometer, a SONY Cell Sorter SH800 can be used to separate fractions with an FSC (forward scattering) value of 300,000 or less.

[0065] In the culturing process, cells derived from human urine are cultured. In one embodiment, the culturing process is performed at least after the dispensing process, or it may be performed after the melting process and before the dispensing process. Through the culturing process performed after the dispensing process, the constructed human urine-derived cells are finally obtained. Regarding the culture medium, culture conditions, and culture period in the culturing process, there are no particular limitations as long as they inhibit the differentiation of human urine-derived cells into plasma cells; culture conditions commonly used by those skilled in the art can be employed. The culture medium in the culturing process is, for example, an initial culture medium, a proliferation culture medium, or a mixture thereof. The culture period in the culturing process is, for example, 1 to 4 weeks.

[0066] In one embodiment, during the culturing process, cells derived from human urine can be cultured in a medium containing a Piezo1 (Piezo-type mechanosensitive ion channel component 1) ion channel agonist. The Piezo1 ion channel is a mechanosensitive calcium ion channel. The inventors have discovered that culturing human urine-derived cells in a medium containing a Piezo1 ion channel agonist enhances the proliferation capacity of these cells. The Piezo1 ion channel can be, for example, Yoda1. Yoda1 is a Piezo1 ion channel agonist with CAS number 448947-81-7, available from suppliers such as Sigma Aldrich (item number SM1558). When cultured in a medium containing Yoda1, the proliferation capacity of human urine-derived cells is enhanced. The concentration of the Piezo1 ion channel agonist added to the medium can be appropriately set by those skilled in the art to a concentration that enhances the proliferation capacity of human urine-derived cells, depending on the type of agonist. The concentration of Yoda1 added to the culture medium can be, for example, 0.1 μg / mL to 100 μg / mL, and as an example, it can be 5 μg / mL.

[0067] One embodiment of the manufacturing method includes a step (collection step) of collecting human urine in a human urine collection system, the human urine collection system comprising: a container (bottle) having a receiving portion for receiving human urine and a sealing mechanism capable of sealing the receiving portion; and antibiotics contained in the receiving portion. Thus, for the human urine collected in the bottle, since the antibiotics dissolve immediately after the human urine is received in the receiving portion, bacterial infection of the collected human urine can be prevented. This improves the success rate (construction success rate) when manufacturing human urine-derived cells from human urine. Furthermore, even if it takes a long time (e.g., more than 4 hours) from collecting human urine to constructing human urine-derived cells, human urine-derived cells can still be constructed. Furthermore, successful construction of human urine-derived cells means recovering the human urine-derived cells as living cells capable of cell division and possessing stem cell-like characteristics. For example, successful construction of human urine-derived cells can be confirmed based on the formation of colonies by culturing the recovered cells. Additionally, for example, successful construction of human urine-derived cells can be confirmed by the following: colonies formed by culturing the recovered cells and obtaining 1.0 × 10⁻⁶ cells from each bottle of urine (e.g., 25–250 mL of urine). 5 More than one cell.

[0068] One embodiment of the manufacturing method includes: a step of concentrating human urine to obtain a human urine concentrate (concentration step); a step of preparing a mixture containing the human urine concentrate, dimethyl sulfoxide, and serum (mixing step); and a step of cryopreserving the mixture (cryopreservation step). By including these steps, one embodiment of the manufacturing method allows for the preparation of human urine-derived cells from the mixture after thawing, even if the cryopreservation process lasts for a long time (e.g., more than one year). That is, one embodiment of the manufacturing method enables the long-term preservation of samples suitable for constructing human urine-derived cells by including these steps. In other words, the composition containing human urine concentrate, dimethyl sulfoxide, and serum is a long-term preservable composition suitable for preparing human urine-derived cells, and this composition can be a composition used in in vitro methods. In this composition, the content of dimethyl sulfoxide is 2.0–50% by volume relative to the total composition, and the content of serum is 15–80% by volume relative to the total composition. This composition can be used to prepare human urine-derived cells. In these cases, from the viewpoint of improving the success rate of construction, the human urine concentrate can be a human urine concentrate obtained within 3 hours after urination in a human subject.

[0069] Alternatively, another embodiment of the manufacturing method may omit the mixing, freezing, and thawing steps if long-term storage is not required. In this case, the human urine concentrate or its dilution (e.g., culture medium dilution) obtained in the concentration step can be directly used in the aliquot or culture step. Furthermore, in another embodiment where the manufacturing method omits the mixing, freezing, and thawing steps, and the human urine concentrate or its dilution obtained in the concentration step is directly used in the aliquot step, from the viewpoint of improving the success rate of the assay, the human urine concentrate or its dilution tested in the aliquot step can be prepared from human urine within 3 hours after urination by a human subject.

[0070] One embodiment of the manufacturing method includes a step of separating cells with a diameter of 10 μm or less from a cell population derived from human urine (a separation step). Since the proportion of human urine-derived cells with a diameter of 10 μm or less is high, including the separation step can increase the proportion of human urine-derived cells in the cell population. This reduces the proportion of impure cells in the constructed human urine-derived cells. In other words, a cell population derived from human urine with a diameter of 10 μm or less can be used to construct human urine-derived cells with a low proportion of impure cells.

[0071] Human urine-derived cells manufactured by a manufacturing method according to one embodiment can, for example, be used as raw material cells in a myotube manufacturing method according to one embodiment of the first aspect. Example

[0072] The present disclosure will be described in more detail below using examples, but the present disclosure is not limited to the following examples.

[0073] <Preparation Example 1: Construction of Human Urine-Derived Cells> [Step 1: Urine Collection] 20,000 units of penicillin and 20,000 μg of streptomycin (Thermo Fisher Scientific, Waltham, MA; 15140-122) and 0.2 μg of amphotericin B (Sigma, St Louis, USA; A2942) were pre-added to sterilized plastic bottles (Corning Incorporated, NY, USA; 430281). Subjects were instructed to urinate into these bottles, and urine was collected. Each bottle yielded 25–250 mL of urine.

[0074] [Step 2: Urine Concentration] The human urine collected in step 1 was aliquoted into multiple 50 mL conical tubes. Each tube was centrifuged at 400 × g at room temperature for 10 minutes to remove the supernatant, leaving only 3 mL. 3 mL of washing buffer (calcium-free) was added to each tube. 2+ and Mg2+ PBS containing 1% penicillin / streptomycin (Thermo Fisher Scientific, Waltham, MA; 15140-122) and 0.5 μg / mL amphotericin B (Sigma, St Louis, USA; A2942) was prepared. The mixture from multiple tubes was collected into a 50 mL conical tube. The tube was centrifuged at 200 × g at room temperature for 10 minutes, and the supernatant was removed, leaving only 3 mL.

[0075] [Step 3: Preparation and cryopreservation of the mixture for cryopreservation] Add 3 mL of CELLBANKER (registered trademark) 1 (Takara Bio, CB011) to the centrifuged tube from step 2 to obtain a mixture for cryopreservation. Place the resulting mixture in a cryo-freezer at -80°C and store it frozen for more than one year.

[0076] [Step 4: Constructing human urine-derived cells from a cryopreservation mixture] The cryopreservation mixture frozen in step 3 was allowed to stand at room temperature and thawed. The thawed cryopreservation mixture was centrifuged at 200×g at room temperature for 5 minutes, and the supernatant was removed, leaving only 3 mL. 6 mL of the initial culture medium (a mixture of equal volumes of high glucose DMEM (GE Healthcare, Logan, UT; SH30022.FS) and Ham's F-12 Nutrient Mix (Thermo Fisher Scientific; 11765-054), with the addition of REGM SingleQuots (Lonza, Basel, Switzerland; CC-4127), 10% tetracycline-free fetal bovine serum (Clontech; 631106), 1% penicillin / streptomycin, and 0.5 μg / mL amphotericin B) to obtain a cell suspension. Fractions with an FSC (forward scattering) value below 300,000 were separated from the obtained cell suspension using a flow cytometer (SONY, CellSorter SH800). Cells with a diameter of less than 10 μm were then separated from the cell suspension. The separated fractions were centrifuged, and the cell pellets were resuspended in 9 mL of the initial culture medium to obtain a cell suspension for culture. 1.5 mL of the obtained cell suspension was added to each well of a gelatin-coated 6-well plate (IWAKI, Shizuoka, Japan; 4810-020) and cultured in an incubator at 37°C with 5% CO2. Add 1.5 mL of initial culture medium daily, and replace it with 2 mL of proliferation medium on day 4 of culture (a mixture of equal volumes of REGM Bullet Kit (Lonza; CC-3190) and high-glucose DMEM, supplemented with 15% fetal bovine serum (FBS) without tetracycline, 0.5% Glutamax (Thermo Fisher Scientific; 35050-061), 0.5% non-essential amino acids (Thermo Fisher Scientific; 11140-050), 2.5 ng / mL basic fibroblast growth factor (bFGF) (Sigma, St Louis, USA; F0291), PDGF-AB (Peprotech, Rocky Hill, NJ; 100-00AB), EGF (Peprotech; AF-100-15), 1% penicillin / streptomycin, and 0.5 μg / mL amphotericin B. Except for amphotericin B / gentamicin from REGM Bullet Kit). Human urine-derived cells will form colonies several days to approximately two weeks after culture begins. Through the above operations, human urine-derived cells were constructed.

[0077] <Experimental Example 1: Success Rate of Constructing Human Urine-Derived Cells Based on Antibiotic-Free Bottles> The success rate of constructing human urine-derived cells from human urine (construction success rate) is evaluated by the proportion of urine samples from which human urine-derived cells were successfully constructed. In the following experimental examples, successful construction of human urine-derived cells was defined as the ability to observe cell colonies and the yield of 1.0 × 10⁶ cells per bottle of urine. 5 The success rate of constructing human urine-derived cells based on the method described in Preparation Example 1 was 93%. Furthermore, even with a maximum of 8 hours of room temperature incubation between steps 1 and 2, no decrease in the construction success rate was observed. On the other hand, when urine was collected from bottles without pre-added antibiotics, and steps 2 and subsequent steps were performed in the same manner as in Preparation Example 1, the construction success rate significantly decreased due to bacterial infection if the room temperature incubation time between steps 1 and 2 exceeded 4 hours. Additionally, when urine was collected from bottles without pre-added antibiotics, and steps 2 and subsequent steps were performed in the same manner as in Preparation Example 1, the construction success rate was 82% even if the room temperature incubation time between steps 1 and 2 was less than 4 hours. These results indicate that collecting human urine from bottles with pre-added antibiotics can improve the construction success rate of human urine-derived cells, and allows for a longer incubation time at room temperature after urine collection.

[0078] <Experimental Example 2: Preservation of a sample prepared based on a cryopreservation mixture, suitable for constructing human urine-derived cells> Using the method described in Preparation Example 1, human urine-derived cells can be constructed without a decrease in construction success rate, even when the cryopreservation mixture is stored for up to 2 years. In contrast, when step 3 is omitted and the collected human urine is directly placed in a refrigerator or freezer for more than 4 hours, followed by step 4 as in Preparation Example 1, the construction success rate is significantly reduced. Therefore, by including step 3—preparing the cryopreservation mixture and performing cryopreservation—long-term preservation of samples suitable for constructing human urine-derived cells becomes possible.

[0079] <Experimental Example 3: Presence or absence of mixed cells in cell sorting> The method described in Example 1 enables the construction of human urine-derived cells with high purity (i.e., few impurity cells). In contrast, when step 4, which involves separating cells with a diameter of 10 μm or less by flow cytometry, is omitted, the proportion of impurity cells in the constructed human urine-derived cells increases. Therefore, by including the step of separating cells with a diameter of 10 μm or less by flow cytometry, it is possible to construct human urine-derived cells with a reduced impurity cell contamination rate.

[0080] <Experimental Example 4: Myotube differentiation capacity of human urine-derived cells dependent on the expression level of the nucleic acid encoding the serine proteoglycan core protein (SRGN gene)> For human urine-derived cells, the study investigated whether changes in myotube differentiation capacity occurred under conditions of SRGN gene overexpression or knockdown. It is known that the myotube differentiation capacity of human urine-derived cells is positively correlated with the expression level of CD90 (Cluster of Differentiation 90, also known as THY1), a marker of mesenchymal stem cells (Non-Patent Literature 2). Based on this, SRGN gene overexpression or knockdown was performed on human urine-derived cells with low or high CD90 expression to investigate whether changes in myotube differentiation capacity occurred.

[0081] Human urine-derived cells with low CD90 expression (CD90(-)) and high CD90 expression (CD90(+)) were separated from those constructed in Preparation Example 1 using the method described in Non-Patent Literature 2. These human urine-derived cells were then seeded in culture dishes or plates (3000–5000 cells / cm²). 2 MYOD1 was introduced into human urine-derived cells by infecting them with the retroviral vector for MYOD1 gene introduction described in Patent Document 1 (hereinafter referred to as "MYOD1 viral vector"). Human urine-derived cells (MYOD1-UDCs) with the MYOD1 gene introduced were selected by adding puromycin to the culture medium 2 days after infection and culturing for 7 days.

[0082] Human urine-derived cells with CD90(-) or CD90(+) transfected with the MYOD1 gene were subjected to overexpression (SRGN-OE) or knockdown (SGRN-KD) of the nucleic acid encoding the serine proteoglycan core protein (SRGN gene). Specifically, the lentiviral vector pLV[Exp]-Bsd-CMV>hSRGN[NM_001321053.2] for SRGN gene transfection, purchased from VectorBuilder (vector map shown in...), was used. Figure 1 The base sequence is shown in sequence number 5) or the lentiviral vector pLV[shRNA]-Bsd-U6>hSRGN for shRNA introduction with SRGN-KD effect (vector map shown in...). Figure 2 The base sequence is shown in sequence number 6. The target sequence in this lentiviral vector is GCTGCAATCCAGACAGTAATT (sequence number 7). MYOD1-UDCs were infected at a concentration of 30 μg / mL. MYOD1-UDCs that underwent SRGN-OE or SRGN-KD were selected by adding blastomycin to the culture medium at a final concentration of 10 μg / mL 2 days after infection and culturing for 7 days.

[0083] The formation of myotubes based on MYOD1-UDCs obtained above was evaluated by immunofluorescence staining. Immunofluorescence staining was performed according to the following protocol: After washing the cells in the cell population with PBS, the cells were fixed with 4% paraformaldehyde and incubated with 0.1% Triton-X at room temperature for 10 minutes. Anti-myosin heavy chain antibody (1:50, R&D, Minneapolis, USA; MAB4470) was used as the primary antibody, and Alexa Fluor 546 goat anti-mouse IgG (H+L) (1:300, Invitrogen; A11003) was used as the secondary antibody. Nuclear staining was performed using DAPI. Images were taken using a fluorescence microscope (BZ-9000 or BZ-X800, KEYENCE, Osaka, Japan) and analyzed using the BZ-X Analyzer (KEYENCE).

[0084] Figure 3 This is a diagram showing the fluorescence images obtained through immunofluorescence staining. Figure 4 To indicate Figure 3 The graph shows the fusion index (the proportion of nuclei contained in the myotubes labeled with MYHC within the cell nuclei labeled with DAPI) in the image, with the results for CD90(-)MYOD1-UDCs shown in (A) and the results for CD90(+)MYOD1-UDCs shown in (B). Figure 4 The results are expressed as mean ± standard deviation (Mean ± SD), and <0.0001 indicates that the p-value in Student's T-test is less than 0.0001. Figure 3 and Figure 4 The results showed that in CD90(-)MYOD1-UDCs with low myodifferentiation capacity, the fusion index was significantly increased through overexpression of the SRGN gene, indicating a significant increase in myodifferentiation capacity. Furthermore, according to... Figure 3 and Figure 4 The results showed that in CD90(+)MYOD1-UDCs with high myodifferentiation capacity, knockdown of the SRGN gene significantly reduced the fusion index, indicating a significant decrease in myodifferentiation capacity. These results suggest that the expression level of the SRGN gene is a factor related to the myodifferentiation capacity of cells. Furthermore, it was also found that increasing the expression level of the SRGN gene can improve the myodifferentiation capacity of cells.

[0085] <Experimental Example 5: Induction of Myodifferentiation in Human Urinary Cells by Adding Sericin to Cell Supernatant> This study investigated whether the addition of seriganine to the culture supernatant promotes myopathic differentiation of MYOD1-UDCs. It is known that seriganine, secreted extracellularly in vivo, binds to CD44 (Cluster of Differentiation 44), a glycoprotein receptor expressed on the cell surface and located in its vicinity. Based on this, the study further investigated whether the effect of adding seriganine to the culture supernatant on myopathic differentiation of MYOD1-UDCs was inhibited by competition with anti-CD44 antibodies.

[0086] In the culture supernatant of CD90(-)MYOD1-UDCs prepared in the same manner as in Experimental Example 4, 25 ng / mL of recombinant human serine proteoglycan (13648-H08H, Sino Biological, rSRGN) and / or 10 ng / mL of anti-CD44 neutralizing antibody (14-0441-82, Affymetrix, anti-CD44) were added, and the mixture was cultured for 14 days. Then, immunofluorescence staining and fluorescence image acquisition were performed in the same manner as in Experimental Example 4.

[0087] Figure 5 This is a diagram showing the fluorescence image obtained through immunofluorescence staining. Figure 6 It means Figure 5 A graph of the fusion index (the proportion of cell nuclei contained in the myotubes, labeled MYHC, within the cell nuclei labeled DAPI that are contained in the image). Figure 6 The results are expressed as mean ± standard deviation (Mean ± SD). 0.2239, <0.0001, and 0.9643 represent the p-values ​​in Student's T-test as 0.2239, <0.0001, and 0.9643, respectively. According to... Figure 5 and Figure 6 The results showed that in the group with serigan added to the culture supernatant (rSRGN+ / anti-CD44-), the fusion index was significantly larger compared to the control group without serigan (rSRGN- / anti-CD44-), indicating a significant improvement in myodifferentiation capacity. Furthermore, this improvement in myodifferentiation capacity was inhibited in the group with both serigan and anti-CD44 neutralizing antibody added to the culture supernatant (rSRGN+ / anti-CD44+), and did not occur in the group with only anti-CD44 neutralizing antibody added (rSRGN- / anti-CD44+). These results indicate that an increase in the concentration of serigan in the cellular environment enhances the myodifferentiation capacity of cells.

[0088] <Experimental Example 6: Promoting the Differentiation of Mouse-Derived Myosatellite Cells into Myotubes by Adding Sericin to Cell Supernatant> The study investigated whether the muscle differentiation promotion observed in Experiment 5 was also observed in cell types other than UDCs, namely mouse-derived muscle satellite cells. Muscle satellite cells are a type of adult stem cell that usually exists in a dormant state but is activated upon muscle injury, proliferating and differentiating into muscle cells such as myotubes.

[0089] Skeletal muscle was harvested from the hind limbs of 10-week-old C57 / BL6J mice (CLEA Co., Ltd., Japan). The harvested skeletal muscle was treated with collagenase and then reacted with antibodies for flow cytometry using standard methods. Antibodies used included those targeting CD31 (Invitrogen, 11-0311-81), a marker for hematopoietic cells; CD45 (Invitrogen, 11-0451-82), a marker for vascular endothelial cells; Scal-1 (BDPharmingen, 553108), a marker for muscle satellite cells; and Integrin-α7 (MBL, K0046-3). Flow cytometry analysis identified CD31(-), CD45(-), Scal-1(-), and Integrin-α7(+) cell populations as muscle satellite cells. After separation, the cells were cultured in DMEM medium containing FBS.

[0090] To the culture supernatant of the mouse-derived myosatellite cells obtained above, 25 ng / mL of recombinant mouse serine proteoglycan (10190-SN-050, R&D, SRGN) was added, and the cells were cultured for 24 hours. After culture, the cells before immobilization were stained with EdU (5-ethynyl-2'-deoxyuridine) according to standard methods to evaluate cell proliferation. Nuclear staining was performed using DAPI. Additionally, for cells prepared and cultured in the same manner as in Example 4, immunofluorescence staining was performed to evaluate differentiation into myotubes. Fluorescence images were obtained for the stained cells as in Example 4.

[0091] Figure 7 This is a diagram showing the fluorescence images obtained through immunofluorescence staining. Figure 8 To indicate Figure 7 A graph showing the proportion of cells stained with DAPI and also with Edu in the proliferative evaluation, i.e., the proportion of proliferating cells. Figure 8 The results are expressed as mean ± standard deviation (Mean ± SD), where ns indicates a p-value greater than or equal to 0.05 in Student's T-test. Figure 9 To indicate Figure 7A graph of the fusion index (the proportion of nuclei contained in the myotubes, labeled MYHC, within the nuclei labeled DAPI) used to evaluate the differentiation capacity of myotubes. Figure 9 The results are expressed as mean ± standard deviation (Mean ± SD). This indicates that the p-value in Student's T-test is less than 0.01. According to... Figures 7-9 The results showed that, compared with the control group (SRGN-) without added serigan, there was no significant difference in the proliferation of myosatellite cells in the group (SRGN+) with added serigan to the culture supernatant. On the other hand, the differentiation of myosatellite cells into myotubes was significantly promoted. This indicates that the increased concentration of serigan in the cellular environment, in addition to UDCs, also enhances the myosatellite differentiation capacity of myosatellite cells.

[0092] <Experimental Example 7: Repair of Muscle Injury in Mice via Administration of Sericin> On day 0, 50 μL of 1.2% BaCl2 aqueous solution was administered intramuscularly to the gastrocnemius muscle of 10-week-old C57 / BL6J mice (CLEA Co., Ltd., Japan). On day 1, the gastrocnemius muscle, which had been administered 50 μL of BaCl2 aqueous solution, was intramuscularly injected with physiological saline or 25 μg / mL of recombinant mouse serine proteoglycan (10190-SN-050, R&D, SRGN). On days 5, 8, or 11, gastrocnemius muscles were harvested and frozen sections were prepared. The sections were fixed with cold acetone for 10 minutes and then incubated with 0.1% Triton for 10 minutes. Next, they were blocked with 10% BSA / PBS solution containing 5% goat serum at room temperature for at least 15 minutes. Then, as primary antibodies, they were incubated overnight at 4°C with mouse anti-eMyHC antibody (1:200) and rat anti-laminus antibody (1:200) diluted in 10% BSA / PBS. In addition, anti-mouse Alexa Fluor (registered trademark) 488 and anti-rat Alexa Fluor (registered trademark) 594 antibodies were used as secondary antibodies and incubated at room temperature for 1 hour in a secondary antibody solution diluted with 10% BSA / PBS. Furthermore, the muscle sections were stained with DAPI using standard methods. Fluorescence images were obtained for the stained muscle sections in the same manner as in Example 4.

[0093] Figure 10 This is a diagram showing the fluorescence images obtained through immunofluorescence staining. Figure 11 To indicate based on and Figure 10Similarly, the fluorescence images obtained were plotted as a graph showing the time-varying proportion of eMyHC-positive muscle fibers (eMyHC+ fibers (%)) as a marker of regenerating muscle fibers. Figure 11 The results are expressed as mean ± standard deviation (Mean ± SD). This indicates a p-value less than 0.0001 in Student's T-test. eMyHC+ fibers (%) are a parameter that increases during the regeneration of muscle fibers after muscle injury. According to... Figure 10 and Figure 11 In the group treated with serigan, a significant increase in eMyHC+ fiber (%) was observed on day 5, followed by a significant decrease on day 8. This indicates that, from a pathological perspective, the group treated with serigan experienced faster muscle recovery, thus promoting muscle repair through serigan administration.

[0094] In addition, for mice that also developed muscle damage and were administered saline or serine proteoglycan, muscle torque was measured on day 5 or day 8. Muscle torque was measured by fixing the mouse's hind limb to a torque measuring machine (S-14154, Takei Machine Industry Co., Ltd.), attaching electrodes, and then inducing muscle contraction of the ankle plantar flexor muscles through electrical stimulation. Figure 12 A graph representing the results of muscle torque measurements standardized to the value of muscle torque measured on day 0. Figure 12 The results are expressed as mean ± standard deviation (Mean ± SD). This indicates that the p-value in Student's T-test is less than 0.001. According to... Figure 12 The results showed that on both days 5 and 8, compared to the group treated with saline, muscle torque was significantly increased in the group treated with serine, and the recovery of muscle torque was faster. This indicates that, from a functional point of view, administration of serine promotes the repair of muscle damage. Therefore, from... Figures 10-12 The results show that serine proteoglycan has a therapeutic effect on muscle damage.

Claims

1. A composition comprising human urine concentrate, dimethyl sulfoxide, and serum.

2. The composition according to claim 1, wherein, The content of the dimethyl sulfoxide is 2.0 to 50% by volume relative to the total amount of the composition. The serum content is 15-80% by volume relative to the total volume of the composition.

3. The composition according to claim 1 or 2, for use in the preparation of human urine-derived cells.

4. A method for manufacturing human urine-derived cells, comprising: The process of concentrating human urine to obtain concentrated human urine. The process for preparing a mixture containing the human urine concentrate, dimethyl sulfoxide, and serum, and The process of freezing and preserving the mixture.

5. A cell population with a diameter of less than 10 μm derived from human urine.

6. A manufacturing method for producing human urine-derived cells, comprising the step of separating cells with a diameter of less than 10 μm from a cell population derived from human urine.

7. A human urine collection system, comprising: A container having a collection section for receiving human urine and a sealing mechanism for sealing the collection section, and Antibiotics stored in the storage compartment.

8. A manufacturing method for producing human urine-derived cells, comprising the step of collecting human urine into the human urine collection system of claim 7.

9. The manufacturing method according to claim 4, 6 or 8, wherein, The human urine referred to is human urine within 3 hours after urination.

10. A muscle differentiation promoter containing serigin or a nucleic acid that promotes the expression of a serigin core protein.

11. The muscle differentiation promoter according to claim 10, wherein it is a muscle differentiation promoter derived from human urine cells or muscle satellite cells.

12. A method of manufacturing a myotube, comprising the step of contacting a cell with serigan or a nucleic acid that promotes the expression of a serigan core protein.

13. The manufacturing method according to claim 12, wherein, The cells in question are derived from human urine.

14. The manufacturing method according to claim 12 or 13, further comprising the step of introducing the MYOD1 gene into the cells.

15. A muscle injury treatment agent comprising serigan or a nucleic acid that promotes the expression of a serigan core protein.

Citation Information

Patent Citations

  • Method for inducing muscular cells using cells in spot urine

    WO2020136696A1